Use of metformin in pediatric age

Pediatric Diabetes

Volumn 12, Issue 6, 2011, Pages 580-588

  Brufani, Claudia ^a   Fintini, Danilo ^a   Nobili, Valerio ^a   Patera, Patrizia Ippolita ^a   Cappa, Marco ^a   Brufani, Mario ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ALT; AMPK; BMI; Children; GI; HbA1c; HOMA IR; Metformin; NAFLD; NASH; Obesity; OCs; PCOS; T2DM

Indexed keywords

METFORMIN;

ABDOMINAL PAIN; ADOLESCENT DISEASE; CHILDHOOD DISEASE; DIARRHEA; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; VOMITING;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS;

EID: 80051933777     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2010.00741.x     Document Type: Review

References (58)

1. Bailey C, Turner RC. Metformin. N Engl J Med 1996: 334: 574-579.
2. Brufani C, Ciampalini P, Grossi A et al. Glucose tolerance status in 510 children and adolescents attending an obesity clinic in Central Italy. Pediatr Diabetes 2010: 11: 47-54.
3. Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009: 155: 469-474.
4. Goran MI, Ball GDC, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 2003: 88: 1417-1427.
5. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009: 32: 1743-1745.
6. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. Type 2 diabetes in children and adolescents. ISPAD clinical practise consensus guidelines 2009 compendium. Pediatr Diabetes 2009: 10 (Suppl. 12): 17-32.
7. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008: 358: 47-54.
8. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009: 21: CD006691.
9. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy 2009: 29: 725-735.
10. Ibanez L, Diaz R, Lopez-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009: 10: 63-76.
11. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002: 51: 2074-2081.
12. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001: 108: 1167-1174.
13. Zou MH, Kirkpatrick SS, Davis BJ et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004: 279: 43940-43951.
14. Elia E, Sander V, Luchetti CG et al. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 2006: 12: 475-481.
15. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyerinsulinemia and a family history of type 2 diabetes. Pediatrics 2001: 107: E55.
16. Srinivasan S, Ambler GR, Baur LA et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006: 91: 2074-2080.
17. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008: 21: 339-348.
18. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008: 152: 817-822.
19. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002: 25: 89-94.
20. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 2007: 30: 790-794.
21. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, De Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001: 86: 3595-3598.
22. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for nondiabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005: 21: 871-879.
23. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003: 26: 138-143.
24. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003: 149: 323-329.
25. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006: 91: 2888-2891.
26. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008: 93: 1841-1845.
27. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002: 137: 25-33.
28. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: 14: CD002967.
29. Nobili V, Manco M, Ciampalini P et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008: 30: 1168-1176.
30. Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother 2004: 38: 776-780.
31. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001: 344: 1343-1350.
32. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002: 346: 393-403.
33. Clarson CL, Mahmud FH, Baker JE et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrinology 2009: 36: 141-146.
34. Wiegand S, l'Allemand D, Hubel D et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010: 163: 585-592.
35. Zeitler P, Epstein L, Grey M et al. The TODAY Study Group. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007: 8: 74-87.
36. Zeitler P. Update on nonautoimmune diabetes in children. J Clin Endocrinol Metab 2009: 94: 2215-2220.
37. Brufani C, Tozzi A, Fintini D et al. Sexual dimorphism of body composition and insulin sensitivity across pubertal development in obese Caucasian subjects. Eur J Endocrinol 2009: 160: 769-775.
38. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2003: 19: 41-47.
39. Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab 2006: 20: 311-330.
40. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009: 30: 1-50.
41. Martin KA, Chang RJ, Ehrmann DA et al. Evaluation and treatment of irsutism in premenopausal women: an Endocrine Society clinical practice and guideline. J Clin Endocrinol Metab 2008: 93: 1105-1120.
42. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001: 29: 160-169.
43. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002: 87: 1555-1559.
44. Ibanez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, De Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small forvgestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002: 87: 5702-5705.
45. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006: 12: 243-253.
46. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008: 93: 4299-4306.
47. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effets of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006: 85: 420-427.
48. Ibanez L, Jaramillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005: 20: 1833-1836.
49. Calef J, Lopez E, Millet A et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007: 92: 3446-3452.
50. Dikensoy E, Balat O, Pence S, Akcali C, Cicek H. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet 2009: 279: 321-327.
51. Unluhizarci K, Ozel D, Tanriverdi F, Karaca Z, Kelestimur F. A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. J Endocrinol Invest 2009: 32: 37-40.
52. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for non-alcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009: 48: 587-596.
53. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008: 28: 13-24.
54. Lavine JE, Schwimmer JB, Molleston JP et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010: 31: 62-70.
55. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomised, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006: 163: 2072-2079.
56. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009: 19: 275-279.
57. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr 2010: 156: 98-102.
58. Casteels K, Fiuews S, van Helvoirt M et al. Metformi therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. Pediatr Diabetes 2010: 11: 61-69.